BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 33068687)

  • 1. Quantitating Interfraction Target Dynamics During Concurrent Chemoradiation for Glioblastoma: A Prospective Serial Imaging Study.
    Stewart J; Sahgal A; Lee Y; Soliman H; Tseng CL; Detsky J; Husain Z; Ho L; Das S; Maralani PJ; Lipsman N; Stanisz G; Perry J; Chen H; Atenafu EG; Campbell M; Lau AZ; Ruschin M; Myrehaug S
    Int J Radiat Oncol Biol Phys; 2021 Mar; 109(3):736-746. PubMed ID: 33068687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of variability in target volume delineation for newly diagnosed glioblastoma: a multi-institutional study from the Korean Radiation Oncology Group.
    Wee CW; Sung W; Kang HC; Cho KH; Han TJ; Jeong BK; Jeong JU; Kim H; Kim IA; Kim JH; Kim SH; Kim S; Lee DS; Lee MY; Lim DH; Park HL; Suh CO; Yoon SM; Kim IH
    Radiat Oncol; 2015 Jul; 10():137. PubMed ID: 26134973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-grade glioma radiation therapy target volumes and patterns of failure obtained from magnetic resonance imaging and 18F-FDOPA positron emission tomography delineations from multiple observers.
    Kosztyla R; Chan EK; Hsu F; Wilson D; Ma R; Cheung A; Zhang S; Moiseenko V; Benard F; Nichol A
    Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1100-6. PubMed ID: 24161427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perfusion magnetic resonance imaging in contouring of glioblastoma patients: Preliminary experience from a single institution.
    Munshi A; Ganesh T; Gupta RK; Vaishya S; Patir R; Sarkar B; Khataniar N; Bansal K; Rastogi K; Mohanti BK
    J Cancer Res Ther; 2020; 16(6):1488-1494. PubMed ID: 33342818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative CEST and MT at 1.5T for monitoring treatment response in glioblastoma: early and late tumor progression during chemoradiation.
    Chan RW; Chen H; Myrehaug S; Atenafu EG; Stanisz GJ; Stewart J; Maralani PJ; Chan AKM; Daghighi S; Ruschin M; Das S; Perry J; Czarnota GJ; Sahgal A; Lau AZ
    J Neurooncol; 2021 Jan; 151(2):267-278. PubMed ID: 33196965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypercellularity Components of Glioblastoma Identified by High b-Value Diffusion-Weighted Imaging.
    Pramanik PP; Parmar HA; Mammoser AG; Junck LR; Kim MM; Tsien CI; Lawrence TS; Cao Y
    Int J Radiat Oncol Biol Phys; 2015 Jul; 92(4):811-9. PubMed ID: 26104935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utilizing 18F-fluoroethyltyrosine (FET) positron emission tomography (PET) to define suspected nonenhancing tumor for radiation therapy planning of glioblastoma.
    Hayes AR; Jayamanne D; Hsiao E; Schembri GP; Bailey DL; Roach PJ; Khasraw M; Newey A; Wheeler HR; Back M
    Pract Radiat Oncol; 2018; 8(4):230-238. PubMed ID: 29730279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inter-fraction dynamics during post-operative 5 fraction cavity hypofractionated stereotactic radiotherapy with a MR LINAC: a prospective serial imaging study.
    Tan H; Stewart J; Ruschin M; Wang MH; Myrehaug S; Tseng CL; Detsky J; Husain Z; Chen H; Sahgal A; Soliman H
    J Neurooncol; 2022 Feb; 156(3):569-577. PubMed ID: 34981300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of [11C]methionine positron emission tomography for target definition of glioblastoma multiforme in radiation therapy planning.
    Matsuo M; Miwa K; Tanaka O; Shinoda J; Nishibori H; Tsuge Y; Yano H; Iwama T; Hayashi S; Hoshi H; Yamada J; Kanematsu M; Aoyama H
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):83-9. PubMed ID: 21095072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility of Gold Fiducial Markers as a Surrogate for Gross Tumor Volume Position in Image-Guided Radiation Therapy of Rectal Cancer.
    van den Ende RPJ; Kerkhof EM; Rigter LS; van Leerdam ME; Peters FP; van Triest B; Staring M; Marijnen CAM; van der Heide UA
    Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1151-1159. PubMed ID: 31476419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upfront boost Gamma Knife "leading-edge" radiosurgery to FLAIR MRI-defined tumor migration pathways in 174 patients with glioblastoma multiforme: a 15-year assessment of a novel therapy.
    Duma CM; Kim BS; Chen PV; Plunkett ME; Mackintosh R; Mathews MS; Casserly RM; Mendez GA; Furman DJ; Smith G; Oh N; Caraway CA; Sanathara AR; Dillman RO; Riley AS; Weiland D; Stemler L; Cannell R; Abrams DA; Smith A; Owen CM; Eisenberg B; Brant-Zawadzki M
    J Neurosurg; 2016 Dec; 125(Suppl 1):40-49. PubMed ID: 27903197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic Contrast-Enhanced MR Imaging of Nonenhancing T2 High-Signal-Intensity Lesions in Baseline and Posttreatment Glioblastoma: Temporal Change and Prognostic Value.
    Hwang I; Choi SH; Park CK; Kim TM; Park SH; Won JK; Kim IH; Lee ST; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH
    AJNR Am J Neuroradiol; 2020 Jan; 41(1):49-56. PubMed ID: 31806595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose Neural Stem Cell Radiation May Not Improve Survival in Glioblastoma.
    Achari R; Arunsingh M; Badgami RK; Saha A; Chatterjee S; Shrimali RK; Mallick I; Arun B
    Clin Oncol (R Coll Radiol); 2017 Jun; 29(6):335-343. PubMed ID: 28188088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diffusion-weighted MRI and ADC versus FET-PET and GdT1w-MRI for gross tumor volume (GTV) delineation in re-irradiation of recurrent glioblastoma.
    Popp I; Bott S; Mix M; Oehlke O; Schimek-Jasch T; Nieder C; Nestle U; Bock M; Yuh WTC; Meyer PT; Weber WA; Urbach H; Mader I; Grosu AL
    Radiother Oncol; 2019 Jan; 130():121-131. PubMed ID: 30219612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in Tumor Volumes and Spatial Locations Relative to Normal Tissues During Cervical Cancer Radiotherapy Assessed by Cone Beam Computed Tomography.
    Chen W; Bai P; Pan J; Xu Y; Chen K
    Technol Cancer Res Treat; 2017 Apr; 16(2):246-252. PubMed ID: 28052737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor Shrinkage During Chemoradiation in Locally Advanced Cervical Cancer Patients: Prognostic Significance, and Impact for Image-Guided Adaptive Brachytherapy.
    Schernberg A; Bockel S; Annede P; Fumagalli I; Escande A; Mignot F; Kissel M; Morice P; Bentivegna E; Gouy S; Deutsch E; Haie-Meder C; Chargari C
    Int J Radiat Oncol Biol Phys; 2018 Oct; 102(2):362-372. PubMed ID: 29920324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamics of FLAIR Volume Changes in Glioblastoma and Prediction of Survival.
    Grossman R; Shimony N; Shir D; Gonen T; Sitt R; Kimchi TJ; Harosh CB; Ram Z
    Ann Surg Oncol; 2017 Mar; 24(3):794-800. PubMed ID: 27766560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison between the Prebolus T1 Measurement and the Fixed T1 Value in Dynamic Contrast-Enhanced MR Imaging for the Differentiation of True Progression from Pseudoprogression in Glioblastoma Treated with Concurrent Radiation Therapy and Temozolomide Chemotherapy.
    Nam JG; Kang KM; Choi SH; Lim WH; Yoo RE; Kim JH; Yun TJ; Sohn CH
    AJNR Am J Neuroradiol; 2017 Dec; 38(12):2243-2250. PubMed ID: 29074633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved dosimetric accuracy with semi-automatic contour propagation of organs-at-risk in glioblastoma patients undergoing chemoradiation.
    Lee S; Stewart J; Lee Y; Myrehaug S; Sahgal A; Ruschin M; Tseng CL
    J Appl Clin Med Phys; 2019 Dec; 20(12):45-53. PubMed ID: 31670900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a candidate biomarker from perfusion MRI to anticipate glioblastoma progression after chemoradiation.
    Khalifa J; Tensaouti F; Chaltiel L; Lotterie JA; Catalaa I; Sunyach MP; Ibarrola D; Noël G; Truc G; Walker P; Magné N; Charissoux M; Ken S; Peran P; Berry I; Moyal EC; Laprie A
    Eur Radiol; 2016 Nov; 26(11):4194-4203. PubMed ID: 26843012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.